SCHEMBL6492174

SCHEMBL6492174

CN(C(=O)OC(C)(C)C)c1ccc(CBr)c(Cl)c1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BRD4 O60885 2/20 0.39
PAX8 Q06710 1/20 0.39
MT-CO2 P00403 1/20 0.38
KAT8 Q9H7Z6 2/20 0.36
KAT6A Q92794 1/20 0.36
KAT5 Q92993 1/20 0.36
NR1H4 Q96RI1 1/20 0.36
CHRNB2 P17787 1/20 0.36
CHRNB4 P30926 1/20 0.36
CHRNA3 P32297 1/20 0.36
CHRNA4 P43681 1/20 0.36
IDO1 P14902 2/20 0.35
RXRA P19793 3/20 0.35
NR1H2 P55055 3/20 0.35
NR1H3 Q13133 3/20 0.35
NPY2R P49146 1/20 0.34
CREBBP Q92793 1/20 0.34
TP53 P04637 1/20 0.33
SMN1; SMN2 Q16637 1/20 0.33
AAK1 Q2M2I8 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27576234 0.90 BRD4 (0.40) BRD4PAX8MT-CO2KAT8KAT6A
SCHEMBL5673919 0.88 MT-CO2 (0.38) MT-CO2IDO1RXRANR1H2NR1H3
SCHEMBL13674398 0.88 BRD4 (0.40) BRD4PAX8MT-CO2KAT8KAT6A
SCHEMBL6493574 0.84 CYP3A4 (0.37) MT-CO2IDO1TP53SMN1; SMN2AAK1
SCHEMBL6490972 0.82 LMNA (0.46) CHRNB2CHRNB4CHRNA3CHRNA4NR1H3
SCHEMBL31425873 0.82 MEN1 (0.42) BRD4PAX8MT-CO2KAT8KAT6A
SCHEMBL6494266 0.80 CHRNA1 (0.43) BRD4PAX8MT-CO2KAT8KAT6A
SCHEMBL27650503 0.80 NR1H4 (0.48) BRD4PAX8MT-CO2KAT8KAT6A
SCHEMBL11002737 0.80 SMN1; SMN2 (0.35) NR1H4NPY2RTP53SMN1; SMN2
SCHEMBL21491334 0.79 BRD4 (0.41) BRD4PAX8MT-CO2KAT8KAT6A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6890934-B2 Sulfonamide compounds and uses thereof as medicines FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2005-05-10 US disclosed
US-20030171396-A1 Sulfonamide compounds and uses thereof as medicines FUJISAWA PHARMACEUTICAL CO. LTD. (JP) 2003-09-11 US disclosed
US-6573274-B1 Treatment of the diseases curable based on a hypoglycemic action, and the diseases curable based on a cGMP-PDE inhibitory action, a smooth muscle relaxing action, a bronchodilating action, a vasodilating action, a smooth muscle FUJISAWA PHARMACEUTICAL CO. LTD. (JP) 2003-06-03 US disclosed
EP-1136492-A1 SULFONAMIDE COMPOUNDS AND USES THEREOF AS MEDICINES FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2001-09-26 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030171396-A1 Sulfonamide compounds and uses thereof as medicines PDE2A, PDE3A, PDE5A BRD4 2621/4885PAX8 2258/4885MT-CO2 4628/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.